Genome Technology Access Center (GTAC)


Richard Head


This core is devoted to the development and implementations of technologies useful in analyzing mutations and aberrant gene expression in human malignancies. The methodologies utilized in the Molecular Core Laboratory include next generation sequencing, high throughput PCR/RT-PCR, gene expression and DNA microarrays, SNP detection, and state-of-the-art bioinformatics analysis. Services that the core offers include:

  • Providing detection of tumor-specific mutations and gene expression patterns in patient samples using conventional and laboratory-developed assays.
  • Providing test validation and direct translation of research observation to clinical cancer genetics analysis
  • Providing a seamless conduit from Siteman Cancer Center’s Tissue Procurement Core so that tumor samples can be accessed, processed and analyzed in an organized fashion.

LOCATION: Cortex Building, Room 205, 4320 Forest Park Ave

PRICING: Please contact the core for current pricing of services offered.

TO ACCESS: Call 314-286-1276 or e-mail

NIH PUBLIC ACCESS POLICY: As of April 7, 2008, the NIH requires investigators with a publication using Siteman (or other NIH-funded) shared resources to submit (or have submitted for them) their final, peer reviewed manuscripts to PubMed Central(PMC) upon acceptance of publication, to be made publicly available within 12 months of publication. Many journals automatically submit these for authors, but Washington University also has assistance available through the Becker Medical Library. Please see or for more information.

PUBLICATION ACKNOWLEDGEMENT: If research supported by the Genome Technology Access Center results in publication, please acknowledge this support by including the following in your publication(s):

We thank the Alvin J. Siteman Cancer Center at Washington University School of Medicine and Barnes-Jewish Hospital in St. Louis, MO. and the Institute of Clinical and Translational Sciences (ICTS) at Washington University in St. Louis, for the use of the Genome Technology Access Center, which provided __________ service. The Siteman Cancer Center is supported in part by an NCI Cancer Center Support Grant #P30 CA091842 and the ICTS is funded by the National Institutes of Health’s NCATS Clinical and Translational Science Award (CTSA) program grant #UL1 TR002345.